Feedback Loop Between Intracranial Atherosclerosis and Cerebral Small Vessel Disease
Launched by CHINESE PLA GENERAL HOSPITAL · Dec 28, 2022
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the relationship between two types of brain diseases: intracranial atherosclerosis (narrowing of the arteries in the brain) and cerebral small vessel disease (problems with the small blood vessels in the brain). The goal is to understand how these conditions affect each other and how they influence disease progression and outcomes. Researchers will use advanced imaging techniques to identify early signs that could help prevent or treat these conditions more effectively.
To participate in this study, you need to be at least 18 years old and have a significant narrowing (50% or more) in at least one of your brain's arteries. Additionally, you should have a good level of mental function. However, if you have serious narrowing in arteries outside the brain, are pregnant, or have certain medical devices that prevent MRI scans, you won't be eligible. If you join the study, you can expect to undergo imaging tests and contribute to important research that may help improve treatment for these brain conditions in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age ≥ 18 years
- • At least one intracranial artery ≥ 50% atherosclerotic stenosis
- • Modified Rankin Scale \< 2
- • Mini-mental State Examination \> 24
- Exclusion Criteria:
- • Concurrent ipsilateral extracranial artery ≥ 50% stenosis
- • Pregnant women
- • Contraindications to magnetic resonance examination (patients with pacemakers, nerve stimulators, artificial metal heart valves and other metal foreign bodies)
About Chinese Pla General Hospital
The Chinese PLA General Hospital, a prominent military medical institution in Beijing, serves as a leading sponsor for clinical trials, focusing on advancing healthcare through innovative research and development. Renowned for its comprehensive medical services and cutting-edge research capabilities, the hospital is committed to improving patient outcomes through rigorous scientific investigation and collaboration with various stakeholders in the healthcare sector. With a multidisciplinary approach and a strong emphasis on evidence-based practices, the Chinese PLA General Hospital aims to contribute significantly to the global medical community by facilitating the development of safe and effective therapeutic interventions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Beijing, Beijing, China
Patients applied
Trial Officials
Jinhao Lyu
Principal Investigator
Chinese PLA General Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials